NEW YORK (GenomeWeb News) – Plant genomics firm Evogene plans to go public in the US with an initial public offering of up to $60 million.

The company, which trades on the Tel Aviv Stock Exchange, filed to go public with the US Securities and Exchange Commission late on Monday, saying it plans to list on the New York Stock Exchange under ticker symbol "EVGN."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A company hopes to capture the genetic diversity in India to power tailored therapeutics, BBC News reports.

Researchers tie variants in seven genes to insomnia risk, Live Science reports.

The US Environmental Protection Agency has approved an RNAi-based insecticide, according to the Atlantic.

In PLOS this week: locus near OAS1 linked to Sjogren's syndrome, rotavirus reassortment events uncovered by sequencing, and more.